![]() 108020004707 nucleic acids Proteins 0.000 claims abstract description 141.150000007523 nucleic acids Chemical class 0.000 claims abstract description 176.229920001184 polypeptide Polymers 0.000 claims abstract description 183.108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims abstract description 187.230000000051 modifying Effects 0.000 title claims description 52.230000028993 immune response Effects 0.000 title claims description 60.101700001016 mbhA Proteins 0.000 title claims abstract description 138.101700065814 LEA2 Proteins 0.000 title claims abstract description 138.101710015954 HVA1 Proteins 0.000 title claims abstract description 138.101700063913 LECT Proteins 0.000 title claims abstract description 142.101700077545 LECC Proteins 0.000 title claims abstract description 143.101700021338 LEC Proteins 0.000 title claims abstract description 144.101700036391 lecA Proteins 0.000 title claims abstract description 145.101700028499 LECG Proteins 0.000 title claims abstract description 145.239000000203 mixture Substances 0.000 title claims abstract description 198.239000002523 lectin Substances 0.000 title claims abstract description 251. ![]() 239000000427 antigen Substances 0.000 title claims abstract description 404.102000038129 antigens Human genes 0.000 title claims abstract description 405.108091007172 antigens Proteins 0.000 title claims abstract description 405.Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Priority to US40482302P priority Critical Priority to US404823P priority Priority to US224661 priority Priority to US10/224,661 priority patent/US7629440B2/en Priority to US48740703P priority Priority to US487407P priority Application filed by OPSANITX LLC, Genitrix LLC filed Critical OPSANITX LLC Priority to PCT/US2003/026072 priority patent/WO2004018698A2/en Application granted granted Critical Publication of ES2441724T3 publication Critical patent/ES2441724T3/en Status Active legal-status Critical Current Anticipated expiration legal-status Critical Links Original Assignee OPSANITX LLC Genitrix LLC Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Segal Elihu Young Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Active Application number ES03793170.6T Other languages Spanish ( es) Lectin compositions and procedures to modulate an immune response to an antigenÄownload PDF Info Publication number ES2441724T3 ES2441724T3 ES03793170.6T ES03793170T ES2441724T3 ES 2441724 T3 ES2441724 T3 ES 2441724T3 ES 03793170 T ES03793170 T ES 03793170T ES 2441724 T3 ES2441724 T3 ES 2441724T3 Authority ES Spain Prior art keywords xxxx antigen lecp cell lectin Prior art date Legal status (The legal status is an assumption and is not a legal conclusion.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |